Treatment of autoimmune diabetes inNODmice by Toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition

Diabetologia

Volumn 55, Issue 12, 2012, Pages 3308-3317

  Kim, D H ^a   Lee, J C ^a   Lee, M K ^a   Kim, K W ^a   Lee, M S ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

Dipeptidyl peptidase 4; Immune tolerance; NOD; TLR2; Treatment; Type 1 diabetes

Indexed keywords

B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; DA 1229; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; INSULIN; PAM3CSK4; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL PROLIFERATION; CELL PROTECTION; CELL VOLUME; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; DIABETES MELLITUS; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HELPER CELL; IC 50; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; INSULIN BLOOD LEVEL; MACROPHAGE; MALE; MONOTHERAPY; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVERSAL REACTION; TREATMENT DURATION; UPREGULATION;

ANIMALS; CELL DIFFERENTIATION; DENDRITIC CELLS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; FLOW CYTOMETRY; LIPOPEPTIDES; MALE; MICE; MICE, INBRED NOD; PIPERAZINES; PREDIABETIC STATE; TOLL-LIKE RECEPTOR 2;

EID: 84868214942     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2723-x     Document Type: Article

References (47)

1. Trudeau JD, Dutz JP, Arany E, Hill DJ, Fieldus WE, Finegood DT (2000) Neonatal beta-cell apoptosis: A trigger for autoimmune diabetes? Diabetes 49:1-7
2. Turley S, Poirot L, Hattori M, Benoist C, Mathis D (2003) Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetesmodel. J ExpMed 198:1527-1537
3. Kim HS, Han MS, Chung KW et al (2007) Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 27:321-333
4. Kim DH, Lee J-C, Kim S et al (2011) Inhibition of autoimmune diabetes by TLR2 tolerance. J Immunol 187:5211-5220
5. Baggio LL, Drucker DJ (1999) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157
6. Xu G, Stoffers DA, Habener JF, Bonner-Weir S (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276
7. Mu J, Woods J, Zhou YP et al (2006) Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55:1695-1704
8. Pospisilik JA, Martin J, Doty T et al (2003) Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52:741-750
9. Mest HJ, Mentlein R (2005) Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 48:616-620
10. Cho JM, Jang HW, Cheon H et al (2011) A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocininduced diabetes by increasing β-cell replication and neogenesis. Diabetes Res Clin Pract 91:72-79
11. Suk K, Kim S, Kim Y-H et al (2001) IFNγ/TNFα synergism as the final effector in autoimmune diabetes: A key role for STAT1/IRF-1 in pancreatic β-cell death. J Immunol 166:4481-4489
12. Kim Y-H, Kim S, Kim K-A et al (1999) Apoptosis of pancreatic β-cells detected in accelerated diabetes of NOD mice: No role of Fas-Fas ligand interaction in autoimmune diabetes. Eur J Immunol 29:455-465
13. Jung HS, Chung KW, Kim JW et al (2008) Loss of autophagy diminishes pancreatic β-cell mass and function with resultant hyperglycemia. Cell Metab 8:318-324
14. Bouwens L, Pipeleers DG (1998) Extra-insular beta cells associated with ductules are frequent in adult human pancreas. Diabetologia 41:629-633
15. Han MS, Chung KW, Cheon HG et al (2009) Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice. Diabetes 58:329-336
16. Tang Q, Adams JY, Penaranda C et al (2008) Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28:687-697
17. Chatenoud L, Bluestone JA (2007) CD3-specific antibodies: A portal of the treatment of autoimmunity. Nat Immunol 7:622-632
18. Orban T, Bundy B, Becker DJ et al (2011) Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. Lancet 378:412-419
19. Hu C, Rodriguez-Pinto D, Du Wet al (2007) Treatment with CD- 20-specific antibody prevents and reverse autoimmune diabetes in mice. J Clin Invest 117:3857-3867
20. Morris MA, McDuffie M, Nadler JL, Ley K (2011) Prevention, but not cure, of autoimmune diabetes in a NOD.scid transfer model by FTY720 despite effective modulation of blood T cells. Autoimmunity 44:115-128
21. Mastrandrea L, Yu J, Behrens T et al (2009) Etanercept treatment in children with new-onset type 1 diabetes. Diabetes Care 32:1244-1249
22. Tarbell KV, Petit L, Zuo X et al (2007) Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med 204:191-201
23. Hasse C, Yu L, Eisenbarth G, Harkholst H (2010) Antigendependent immunotherapy of non-obese diabetic mice with immature dendritic cells. Clin Exp Immunol 160:331-339
24. Nussbaum G, Zanin-Zhorov A, Quintana F, Lider O, Cohen IR (2006) Peptide p277 of HSP60 signals T cells: Inhibition of inflammatory chemotaxis. Int Immunol 18:1413-1419
25. Allen HF, Klingensmith GJ, Jensen PE, Simoes E, Hayward A, Chase HP (1999) Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. Diabetes Care 22:1703-1707
26. Group TDS (2002) Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 202:346
27. Ludvigsson J, Faresjö M, Hjorth M et al (2008) GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359:1909-1920
28. Alipio Z, LiaoW, Roemer EJ et al (2010) Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic beta-like cells. Proc Natl Acad Sci USA 107:13426-13431
29. Agudo J, Ayuso E, Jimenez V et al (2008) IGF-I mediates regeneration of endocrine pancreas by increasing beta cell replication through cell cycle protein modulation in mice. Diabetologia 52:1862-1872
30. Lavine JA, Raess PW, Davis DB et al (2008) Overexpression of pre-pro-cholecystokinin stimulates beta-cell proliferation in mouse and human islets with retention of islet function. Mol Endocrinol 22:2716-2728
31. Ogawa N, List JF, Habener JF, Maki T (2004) Cure of overt diabetes in NOD mice by transient treatment with antilymphocyes serum and exentin-4. Diabetes 53:1700-1705
32. Sherry NA, Chen W, Kushner JA et al (2007) Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD-3 monoclonal antibody by enhancing recovery of β-cells. Endocrinology 148:5136-5144
33. Suarez-Pinzon WL, Cembrowski GS, Rabinovitch A (2009) Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycemia in non-obese diabetic mice. Diabetologia 52:1680-1682
34. Suarez-Pinzon WL, Lakey JR, Brand SJ, Rabinovitch A (2005) Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet β-cells from pancreatic duct cells and an increase in functional β-cell mass. J Clin Endocrinol Metab 90:3401-34091
35. Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch A (2008) Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57:3281-3288
36. Tian L, Gao J, Hao J et al (2010) Reversal of new-onset diabetes through modulating inflammation and stimulating β-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 151:3049-3060
37. Dor Y, Brown J, Martinez OI, Melton DA (2004) Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429:41-46
38. Dunning BE, Foley JE, Ahren B (2005) Alpha cell function in health and disease: Influence of glucagon-like peptide-1. Diabetologia 48:1700-1713
39. Pechhold K, Zhu X, Harrison VS et al (2009) Dynamic changes in pancreatic endocrine cell abundance, distribution, and function in antigen-induced and spontaneous autoimmune diabetes. Diabetes 58:1175-1184
40. Kim S-J, Nian C, Doudet DJ, McIntosh CH (2009) Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T cell modulation. Diabetes 58:641-651
41. Reinhold D, Goihl A, Wrenger S et al (2009) Role of dipeptidyl peptidase IV (DPPIV)-like enzymes in T lymphocyte activation: Investigations in DPPIV/CD26-knockout mice. Clin Chem Lab Med 47:268-274
42. Vora KA, Porter G, Peng R et al (2009) Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T celldependent immune responses. BMC Immunol 10:1-11
43. Filippi CM, Ehrhartd K, Estes EA, Larsson P, Oldham JE, von Herrath M (2011) TLR2 signaling improves immunoregulation to prevent type 1 diabetes. Eur J Immunol 41:1399-1409
44. Höhlich BJ, Wiesmüller KH, Haas B et al (2003) Induction of an antigen-specific immune response and partial protection of cattle against challenge infection with foot-and-mouth disease virus (FMDV) after lipopeptide vaccination with FMDV-specific B cell epitopes. J Gen Virol 84:3315-3324
45. Kudryashov V, Glunz PW,Williams LJ, Hintermann S, Danishefsky D, Lloyd KO (2001) Toward optimized carbohydrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewisy conjugates in mice. Proc Natl Acad Sci USA 98:3264-3269
46. Zhu X, Ramos TV, Gras-Masse H, Kaplan BE, BenMohamed L (2004) Lipopeptide epitopes extended by an N-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur J Immunol 34:3102-3114
47. Seth A, Yasutomi Y, Jacoby H et al (2000) Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropostivie individuals. AIDS Res Hum Retroviruses 16:337-343